Oncologists Turn to Off-Label Drug Use for Rare Cancers: What to Know

In this op-ed, TRACER Director Taran Gujral, PhD, highlights how oncologists are increasingly turning to off-label use of approved drugs to treat rare cancers. Guided by molecular profiling and tumor boards, this approach helps personalize care when clinical trials and approved therapies aren’t available. By embracing and advocating for off-label strategies, clinicians can help pave the way for more comprehensive care — and better outcomes — for patients with rare cancers.

Read the full story here:

https://www.oncologynewscentral.com/rare-cancers-and-disorders/oncologists-turn-to-off-label-drug-use-for-rare-cancers-what-to-know